uniQure Follow-Up Phase IIb Data on Hemophilia Trial at ASH19

~ Sustained FIX Activity at Therapeutic Levels¹ Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~

~ Zero Bleeds and No Requirement for Immunosuppression in One Year Following Dosing with Etranacogene Dezaparvovec ~

~ Long-term Clinical Benefit and Tolerability of AMT-060 Maintained in All Patients Through up to 4 Years of Follow-Up ~

~ Investor Webcast on Monday, December 9, 2019 at 7:00 a.m. EST ~

https://www.marketscreener.com/UNIQURE-N-V-15712155/news/uniQure-Announces-One-Year-Follow-Up-Data-from-the-Phase-IIb-Study-of-Etranacogene-Dezaparvovec-and-29698545/